問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

吳建志

Recruiting

List

9Cases

2025-09-01 - 2029-12-31

Phase II

Not yet recruiting
A Phase 2, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V540A in Healthy Females 16 to 26 Years of Age

  • Condition/Disease

    Healthy Females

  • Test Drug

    Injection

Participate Sites
6Sites

Recruiting6Sites

2024-11-01 - 2025-11-15

Phase I

Completed
A Phase I, Double-Blinded, Randomized, Vehicle-Controlled, and Single-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ENERGI-F705 Tablets in Healthy Volunteers

  • Condition/Disease

    Healthy Volunteers

  • Test Drug

    tablet

Participate Sites
1Sites

Recruiting1Sites

2024-10-01 - 2026-12-31

Phase I

Active
A Phase I, Randomized, Double-blinded, Placebo- Controlled First-in-human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of J4 Dry Powder Capsule after Oral Administration of Single and Multiple Ascending Doses to Healthy Adults

  • Condition/Disease

    Healthy Adults

  • Test Drug

    capsule

Participate Sites
1Sites

Recruiting1Sites

2023-09-01 - 2026-06-30

Phase III

Active
A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Subunit Inactivated Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age

  • Condition/Disease

    NA

  • Test Drug

    intramuscular injection

Participate Sites
5Sites

Recruiting5Sites

2023-09-01 - 2027-12-31

Phase I

Active
A Phase I, Double-Blind, Placebo-Controlled, Randomized, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Food Effect and Potential Efficacy of PS1 in Human

  • Condition/Disease

    PS1

  • Test Drug

    tablet

Participate Sites
1Sites

Recruiting1Sites

2023-12-01 - 2026-12-31

Phase I/II

Active
xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
3Sites

Recruiting3Sites

2019-07-01 - 2022-09-30

Phase I

A single-blinded, randomized, placebo-controlled, dose escalation, Phase 1 study to investigate the safety, tolerability, pharmacokinetic and pharmacodynamic profiles of UB-852 after a single subcutaneous administration in healthy male adults

  • Condition/Disease

    Anemia in chronic kidney disease

  • Test Drug

    UB-852

Participate Sites
1Sites

Recruiting1Sites

2023-09-01 - 2026-06-30

Phase III

A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Quadrivalent Influenza Vaccine in Adults ≥65 Years of Age

  • Condition/Disease

    Influenza, Human

  • Test Drug

    Fluad Tetra

Participate Sites
5Sites

Not yet recruiting4Sites

Recruiting1Sites

2020-09-25 - 2022-11-17

Phase I/II

A Phase I/IIa Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Efficacy of AR100DP1 in Healthy Subjects, and Subjects with Mild to Moderate Atopic Dermatitis

  • Condition/Disease

    Atopic Dermatitis (AD)

  • Test Drug

    AR100DP1

Participate Sites
2Sites

Not yet recruiting1Sites

Recruiting1Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB